Biotie announces top-line results from nepicastat (SYN117) study in cocaine dependence
Biotie announced top-line results from a Phase 2 clinical study with nepicastat (SYN117) in cocaine-dependent patients. When compared to placebo, nepicastat did not meet the primary efficacy endpoint of an increased proportion of subjects remaining abstinent from cocaine during the treatment. January 30, 2015